Brief Summary

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Approved for marketing
Hemoglobinuria, Paroxysmal

Drug: eculizumab
600mg IV every week and 900mg IV every 2 weeks

Eligibility Criteria

Inclusion Criteria:

- PNH;

- At least 18 years old

- Avoid conception; and

- Willing and able to give written informed consent

Exclusion Criteria:

- Active bacterial infection

- Participation in any other drug trial

- Pregnant breast feeding, or intending to conceive

- Not vaccinated against N meningitidis

Eligibility Gender
Eligibility Age
Minimum: 18 Years
United States

Anthony Botti
Livingston, New Jersey,

Alexion Pharmaceuticals
NCT Number
MeSH Terms
Hemoglobinuria, Paroxysmal